Recent advances in the treatment of patients with obesity and chronic kidney disease
AbstractObesity is a chronic disease characterised by excess adiposity, which impairs health. The high prevalence of obesity raises the risk of long-term medical complications including type 2 diabetes and chronic kidney disease. Several studies have focused on patients with obesity, type 2 diabetes...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Annals of Medicine |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/07853890.2023.2203517 |
| _version_ | 1797353745666801664 |
|---|---|
| author | Roshaida Abdul Wahab Ricardo V. Cohen Carel W. le Roux |
| author_facet | Roshaida Abdul Wahab Ricardo V. Cohen Carel W. le Roux |
| author_sort | Roshaida Abdul Wahab |
| collection | DOAJ |
| description | AbstractObesity is a chronic disease characterised by excess adiposity, which impairs health. The high prevalence of obesity raises the risk of long-term medical complications including type 2 diabetes and chronic kidney disease. Several studies have focused on patients with obesity, type 2 diabetes and chronic kidney disease due to the increased prevalence of diabetic kidney disease. Several randomized controlled trials on sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 analogues, and bariatric surgery in diabetic kidney disease showed renoprotective effects. However, further research is critical to address the treatment of patients with obesity and chronic kidney disease to lessen morbidity.Key messageObesity is a driver of chronic kidney disease, and type 2 diabetes, along with obesity, accelerates chronic kidney disease.Several randomized controlled trials on sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 analogues, and bariatric surgery in diabetic kidney disease demonstrate the improvement of renal outcomes.There is a need to address the treatment of patients with obesity and CKD to lessen morbidity. |
| first_indexed | 2024-03-08T13:34:26Z |
| format | Article |
| id | doaj.art-84e0734e58cc4cff90f794e283776db7 |
| institution | Directory Open Access Journal |
| issn | 0785-3890 1365-2060 |
| language | English |
| last_indexed | 2024-03-08T13:34:26Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Annals of Medicine |
| spelling | doaj.art-84e0734e58cc4cff90f794e283776db72024-01-16T19:13:22ZengTaylor & Francis GroupAnnals of Medicine0785-38901365-20602023-12-0155110.1080/07853890.2023.2203517Recent advances in the treatment of patients with obesity and chronic kidney diseaseRoshaida Abdul Wahab0Ricardo V. Cohen1Carel W. le Roux2Diabetes Complications Research Centre, University College Dublin, Dublin, IrelandCenter for the Treatment of Obesity and Diabetes, Hospital Oswaldo Cruz, Sao Paulo, BrasilDiabetes Complications Research Centre, University College Dublin, Dublin, IrelandAbstractObesity is a chronic disease characterised by excess adiposity, which impairs health. The high prevalence of obesity raises the risk of long-term medical complications including type 2 diabetes and chronic kidney disease. Several studies have focused on patients with obesity, type 2 diabetes and chronic kidney disease due to the increased prevalence of diabetic kidney disease. Several randomized controlled trials on sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 analogues, and bariatric surgery in diabetic kidney disease showed renoprotective effects. However, further research is critical to address the treatment of patients with obesity and chronic kidney disease to lessen morbidity.Key messageObesity is a driver of chronic kidney disease, and type 2 diabetes, along with obesity, accelerates chronic kidney disease.Several randomized controlled trials on sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 analogues, and bariatric surgery in diabetic kidney disease demonstrate the improvement of renal outcomes.There is a need to address the treatment of patients with obesity and CKD to lessen morbidity.https://www.tandfonline.com/doi/10.1080/07853890.2023.2203517Obesitydiabetic kidney diseasesodium-glucose cotransporter 2 inhibitorsglucagon-like peptide-1 analoguesbariatric surgerychronic kidney disease |
| spellingShingle | Roshaida Abdul Wahab Ricardo V. Cohen Carel W. le Roux Recent advances in the treatment of patients with obesity and chronic kidney disease Annals of Medicine Obesity diabetic kidney disease sodium-glucose cotransporter 2 inhibitors glucagon-like peptide-1 analogues bariatric surgery chronic kidney disease |
| title | Recent advances in the treatment of patients with obesity and chronic kidney disease |
| title_full | Recent advances in the treatment of patients with obesity and chronic kidney disease |
| title_fullStr | Recent advances in the treatment of patients with obesity and chronic kidney disease |
| title_full_unstemmed | Recent advances in the treatment of patients with obesity and chronic kidney disease |
| title_short | Recent advances in the treatment of patients with obesity and chronic kidney disease |
| title_sort | recent advances in the treatment of patients with obesity and chronic kidney disease |
| topic | Obesity diabetic kidney disease sodium-glucose cotransporter 2 inhibitors glucagon-like peptide-1 analogues bariatric surgery chronic kidney disease |
| url | https://www.tandfonline.com/doi/10.1080/07853890.2023.2203517 |
| work_keys_str_mv | AT roshaidaabdulwahab recentadvancesinthetreatmentofpatientswithobesityandchronickidneydisease AT ricardovcohen recentadvancesinthetreatmentofpatientswithobesityandchronickidneydisease AT carelwleroux recentadvancesinthetreatmentofpatientswithobesityandchronickidneydisease |